[1] It is authorized to make binding regulations growing out of health reform bills passed by lawmakers, along with routine decisions regarding healthcare in Germany.

[4] The directives issued by the committee are legally binding for publicly insured persons as well as for the providers and payers of health care.

[6] On June 17, 2010, the Committee removed the usage of glinides from general prescription guidelines for the reduction of human glucose levels.

It justified its decision by referring to the conclusion of the Institute for Quality and Efficiency in Health Care that proof of efficacy was lacking.

[7] In 2013, the Committee issued a preliminary decision ruling that a fixed dose combination of Stribild does not offer a benefit over Atripla for HIV treatment.